Professional Summary
Professional Overview
Lars Van Der Veen is the Founder and Chief Strategy Officer (CSO) of iOnctura, a biopharmaceutical company focused on developing innovative cancer therapies. With over 20 years of experience in the pharmaceutical industry, he brings a wealth of expertise in drug discovery, project management, and strategic alliance development.
Experience Summary
Current Role
As the Founder and CSO of iOnctura, Lars is responsible for setting the company's strategic direction and overseeing the development of its pipeline of novel cancer treatments. Under his leadership, iOnctura has established strategic partnerships with several industry-leading organizations, accelerating the advancement of its research and development initiatives.
Career Progression
Prior to founding iOnctura, Lars held various leadership roles at prominent pharmaceutical companies. As the Director of Alliance Management at Merck Group, he was instrumental in forging and managing strategic collaborations that drove the company's growth and innovation. Earlier in his career, he served as a Discovery Project Manager at Merck Serono and a Project Leader at Boehringer Ingelheim, where he led multidisciplinary teams in the successful progression of drug candidates through the development pipeline.
Academic Background
Lars holds a Ph.D. in Pharmaceutical Sciences from the University of Utrecht, Netherlands, where he specialized in drug discovery and development. His academic excellence and research contributions have been recognized through various awards and publications in peer-reviewed journals.
Areas of Expertise
- Drug discovery and development
- Project management and team leadership
- Strategic alliance and partnership development
- Pharmaceutical industry regulations and best practices
- Cancer biology and targeted therapy research
Professional Impact
Throughout his career, Lars has played a pivotal role in advancing the development of innovative cancer therapies. His leadership and strategic vision have resulted in the successful progression of multiple drug candidates from the discovery phase to clinical trials, positively impacting the lives of cancer patients. As the Founder and CSO of iOnctura, Lars continues to drive the company's mission to develop transformative cancer treatments and make a meaningful difference in the lives of those affected by this devastating disease.
Conclusion
With his extensive experience, proven track record of success, and unwavering commitment to innovation, Lars Van Der Veen is a respected leader in the biopharmaceutical industry. As the Founder and CSO of iOnctura, he is poised to continue driving the company's growth and making a lasting impact on the field of cancer research and treatment.
